BIO: Science in Action
Science in action may have been the unofficial theme of BIO 2024 as life sciences companies from across the globe unveiled their latest drug development research.
Companies offered insight into therapeutic modalities, including cutting-edge cell and gene therapies which are changing the treatment landscape for rare, genetic diseases. Like a beacon of hope, science is shining its light on new approaches that offer patients and their families a glimpse of a future where some diseases are no longer a death sentence, and in some cases, can be functionally cured.
At BIO, companies highlighted advances in cell and gene therapies like the newly approved gene therapies for sickle cell disease, as well as innovations in CAR-T cell therapies targeting cancer and autoimmune diseases.
Industry leaders discussed advances in the manufacturing processes for cell therapies. They also emphasized the importance of reducing costs and increasing efficiency. Innovations in automation and new technologies are addressing these challenges, potentially making cell therapies more accessible and scalable.
Biomanufacturing is an increasingly important sector of the industry, which has a significant impact on the U.S. economy. According to a new report shared at BIO, The Economic Impact of the U.S. Industrial Bioeconomy, in 2023 the biotechnology industry contributed $210.4 billion to the Gross Domestic Product and added 643,992 domestic jobs.
During BIO, experts discussed payment models for cutting edge, one-and-done, cell and gene therapies. A single administration of these treatments can offer a functional cure to various diseases, such as the recently approved therapies for sickle cell disease, melanoma and metachromatic leukodystrophy. Current payment models cover long-term treatment options. A new, holistic method is needed for these advanced therapies, panelists argued.
Patients and patient advocates addressed alternative funding programs (AFPs) designed to remove specialty drugs from an insurance company’s formulary to have patients seek access to the medications through a drug maker’s patient assistance programs. Advocates also discussed Prescription Drug Affordability Boards designed to determine the price of drugs manufacturers can charge in different states.
Supply chain issues that became noticeable during the shutdowns caused by the Covid-19 pandemic were also front and center during the conference. The shortfall of raw materials for drug development hindered manufacturing efforts for multiple products. During a fireside chat at BIO, FDA Commissioner Dr. Robert Califf noted that a deteriorating political relationship between the United States and China could negatively affect the supply chain for raw materials needed to manufacture medications our citizens depend upon.
If something goes wrong with the relationship with China, we’d be cut off completely.
Califf told BIO President & CEO John F. Crowley.
In agreement, Crowley, who founded Amicus Therapeutics, noted that biotechnology is a national security imperative. Crowley pointed to supply chain disruptions during the global pandemic that negatively impacted ongoing clinical programs and reliable distribution of medications. Another global pandemic or volatile political relations could be disastrous for drug manufacturers if those supply chains are cut off.
Other key topics included discussions of pressing industry issues, such as artificial intelligence and regulatory innovation. Panel members discussed the benefits, challenges, and regulatory implications of AI adoption in healthcare. In addition to the role of AI in healthcare, another panel focused on the role AI plays in transforming research and development of new therapies.
Workforce development also took center stage at BIO. Industry executives discussed the importance of fostering diversity and developing inclusive environments that can drive innovation. They also shared hiring strategies and best practices for building effective teams.
BIO looks toward the future with the next international conference planned for Boston in the summer of 2025.
